Glucocorticiods, 11β-hydroxysteroid dehydrogenase type 1, and visceral obesity;Glucocorticoïdes, 11β-hydroxystéroïde déshydrogénase de type 1 et obésité viscérale

Medecine/Sciences

Volumn 19, Issue 4, 2003, Pages 473-476

  Paulmyer Lacroix, Odile ^a   Boullu Ciocca, Sandrine ^a,b   Oliver, Charles ^a,b   Dutour, Anne ^a,b   Grino, Michel ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; GLUCOCORTICOID; HYDROCORTISONE;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INACTIVATION; HUMAN; HUMAN TISSUE; MEDIATOR RELEASE; METABOLIC DISORDER; OBESITY; REVIEW;

EID: 0037390853     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2003194473     Document Type: Review

References (20)

1. Vague J. La différentiation sexuelle, facteur déterminant des formes de l'obésité. Presse Med 1947; 30: 339-40.
2. Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocrinol Rev 1996; 17: 245-61.
3. Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11β-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 2001; 15: 61-78.
4. Walker BR. Steroid metabolism in metabolic syndrome X. Best Pract Res Clin Endocrinol Metab 2001; 15: 111-22.
5. Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-21.
6. Björntorp P, Rosmond R. The metabolic syndrome: a neuroendocrine disorder? Br J Nutr 2000; 83: S49-57.
7. Jessop DS, Dallman MF, Fleming D, Lightman SL. Resistance to glucocorticoid feedback in obesity. J Clin Endocrinol Metab 2001; 86: 4109-14.
8. Rask E, Walker BR, Söderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002; 87: 3330-6.
9. Livingstone DEW, Jones GC, Smith K, et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000; 141: 560-3.
10. Masuzaki H, Paterson J, Shinyama H, et at al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-70.
11. Katz JR, Mohamed-Ali V, Wood PJ, Yudkin JS, Coppack SW. An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Clin Endocrinol 1999; 50: 63-8.
12. Bujalska IW, Kumar S, Stewart PM. Does central obesity reflect Cushing's disease of the omentum? Lancet 1997; 349: 1210-3.
13. Bujalska IJ, Kumar S, Hewinson M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 1999; 140: 3188-96.
14. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002; 87: 2701-5.
15. Bujalska IJ, Walker EA, Hewinson M, Stewart PM. A switch in dehydrogenase to reductase activity of 11β-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 2002; 87: 1205-10.
16. Bastelica D, Morange P, Berthet B, et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002; 22: 173-8.
17. Seckl JR, Walker BR. 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001; 142: 1371-6.
18. Weaver JU, Thaventhiran L, Nooran N, et al. The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol (Oxf) 1994; 41: 639-48.
19. Berger J, Tanen M, Elbrecht A, et al. Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 2001; 276: 12629-35.
20. Kelly IE, Han TS, Walsh K, Leon MEJ. Effects of a thiazalidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-93.